The observed downregulation of AKR1B10 provides crucial experimental support for our computational predictions and pharmacological hypotheses, suggesting that XYJDY can effectively regulate the expression of this critical target in a psoriasis-like inflammation model. This evidence concerns the gene AKR1B10 and psoriasis.